Ronacaleret (hydrochloride)

Ronacaleret hydrochloride (SB 751689A) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret hydrochloride (SB 751689A) is used for the study of postmenopausal osteoporosis[1].

Product Specifications

CAS Number

[702686-96-2]

Product Name Alternative

SB 751689A

UNSPSC

12352005

Target

CaSR

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ronacaleret-hydrochloride.html

Purity

99.81

Solubility

10 mM in DMSO

Smiles

O=C(O)CCC1=CC(F)=C(F)C(OC[C@H](O)CNC(C)(C)CC2CC3=C(C=CC=C3)C2)=C1.Cl

Molecular Formula

C25H32ClF2NO4

Molecular Weight

483.98

References & Citations

[1]György Szabó, et al. Discovery of dihydropyrazino-benzimidazole derivatives as metabotropic glutamate receptor-2 (mGluR2) positive allosteric modulators (PAMs) . Eur J Med Chem. 2020 Jan 15:186:111881.|[2]Tsuneo Takenaka , et al. Antialbuminuric actions of calcilytics in the remnant kidney. Am J Physiol Renal Physiol. 2015 Aug 1;309 (3) :F216-26.|[3]Marta Johnson, et al. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin. Drug Metab Dispos. 2017 Jan;45 (1) :27-34.